P3 trial saving #COVID19-induced #ARDS patients. Extraordinary survival outcomes seen in pilot study (83% survival in ventilator-dependent patients w/ moderate/severe ARDS): https://buff.ly/2Ky4f3s More very soon.
This surely speaks to the inner confidence Mesoblast has and the effectiveness of the trial.Trial update must be imminent.
David Oxley@CellularMedici2·Jul 12P3 trial saving...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.028(2.43%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.09 | $4.846M | 4.381M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 16090 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 13331 | 5 |
View Market Depth
| Last trade - 11.14am 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.028 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.09 | 941558 | ||
| Last updated 11.33am 09/05/2024 ? | |||||
| MSB (ASX) Chart |